Share

June 01, 2021; 96 (22) Editorial

Cognitive Heterogeneity in Alzheimer Clinical Trials

Harnessing Noise to Achieve Meaningfulness

Rachel F. Buckley, David S. Knopman
First published May 31, 2021, DOI: https://doi.org/10.1212/WNL.0000000000012027
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
120

Share

Article Information

vol. 96 no. 22 1017-1018
DOI: 
https://doi.org/10.1212/WNL.0000000000012027
PubMed: 
34550902
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published May 31, 2021.
Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Rachel F. Buckley, PhD and
    2. David S. Knopman, MD
  1. Rachel F. Buckley, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease (2 years: 2014-2016) Special editor of Alzheimer's & Dementia DADM sub-journal (2020-2021) Editorial Board of Neurology (2020-)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NHMRC Dementia Research Fellowship, APP1105576, CIA, 2016-2020 NIH-NIA K99/R00 Pathway to Independence award: 2020- 2024

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Alzheimer's Association Research Fellowship (2020- 2023)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. David S. Knopman, MD
    3. Scientific Advisory Boards:

    1. DIAN study DSMB (Sept 2013 - July 2019; August 2020 - present).

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Omsbudsman Neurology, previously; Scientific Integrity officer, currently

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) A4 clinical trial partially funded by Lilly (site PI) (2) Biogen Alzheimer Study (site PI)

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer’s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (R.F.B.), Massachusetts General Hospital and Harvard Medical School; Center for Alzheimer Research and Treatment (R.F.B.), Department of Neurology, Brigham and Women's Hospital, Boston, MA; Melbourne School of Psychological Science (R.F.B.), University of Melbourne, VIC, Australia; and Department of Neurology (D.K.), Mayo Clinic, Rochester, MN.
  1. Correspondence
    Dr. Buckley rfbuckley{at}mgh.harvard.edu
View Full Text

Article usage

Article usage: May 2021 to April 2023

AbstractFullPdfSource
May 2021155146Highwire
Jun 20216968454Highwire
Jul 20217888Highwire
Aug 20215932Highwire
Sep 2021135167Highwire
Oct 2021257710Highwire
Nov 202127685Highwire
Dec 20217745Highwire
Jan 20227643Highwire
Feb 202211151Highwire
Mar 20228000Highwire
Apr 20228115Highwire
May 20223223Highwire
Jun 20224832Highwire
Jul 20224401Highwire
Aug 20223412Highwire
Sep 20223620Highwire
Oct 20222501Highwire
Nov 20222900Highwire
Dec 20222752Highwire
Jan 20234210Highwire
Feb 20232000Highwire
Mar 20232542Highwire
Apr 20231721Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles